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Angiogenesis is critical for growth and metastatic spread of solid tumours. It is tightly controlled by speciﬁc regulatory factors.
Vascular endothelial growth factor has been implicated as the key factor in tumour angiogenesis. In the present studies we
evaluated the effects of blocking vascular endothelial growth factor production by antisense phosphorothioate
oligodeoxynucleotides on the growth and angiogenic activity of a pre-clinical model of renal cell carcinoma (Caki-1). In
vitro studies showed that treating Caki-1 cells with antisense phosphorothioate oligodeoxynucleotides directed against vascular
endothelial growth factor mRNA led to a reduction in expressed vascular endothelial growth factor levels sufﬁcient to impair
the proliferation and migration of co-cultured endothelial cells. The observed effects were antisense sequence speciﬁc, dose
dependent, and could be achieved at a low, non-toxic concentration of phosphorothioate oligodeoxynucleotides. When
vascular endothelial growth factor antisense treated Caki-1 cells were injected into nude mice and evaluated for their
angiogenic potential, the number of vessels initiated were approximately half that induced by untreated Caki-1 cells. To test
the anti-tumour efﬁcacy of vascular endothelial growth factor antisense, phosphorothioate oligodeoxynucleotides were
administrated to nude mice bearing macroscopic Caki-1 xenografts. The results showed that the systemic administration of
two doses of vascular endothelial growth factor antisense phosphorothioate oligodeoxynucleotides given 1 and 4 days after
the tumours reached a size of *200 mm
3 signiﬁcantly increased the time for tumours to grow to 1000 mm
3.
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Angiogenesis, a complex multi-step process involving the forma-
tion of new blood vessels from pre-existing ones, is tightly
regulated by both positive and negative regulatory factors (Risau,
1997). These regulators, which included pro-angiogenic factors
such as basic ﬁbroblast growth factor (bFGF) (Wang and Becker,
1997), angiogenin (Gho and Chae, 1997) and vascular endothelial
growth factor (VEGF) (Kim et al, 1993; Asano et al, 1995; Borg-
strom et al, 1996; Cheng et al, 1996; Saleh et al, 1996), as well
as angiostatic peptides such as endostatin (O’Reilly et al, 1997;
Perletti et al, 2000), angiostatin (O’Reilly et al, 1994a,b) and
thrombospondin (Folkman and Shing, 1992; Folkman, 1995) are
potential targets for anti-angiogenic therapy of solid tumours
(Folkman, 1971; Bicknell and Harris, 1992; Harris et al, 1994;
Denekamp, 1999).
Vascular endothelial growth factor is an endothelial cell speciﬁc
mitogen, secreted as a 45 kDa homo dimer protein. There are ﬁve
human isoforms derived from alternative splicing (VEGF 121, 145,
165, 189, 206) (Houck et al, 1991). VEGF121 and VEGF165 are the
only soluble isoforms and also the most abundant, with VEGF165
being the most powerful stimulator of endothelial cell proliferation
(Soker et al, 1997). VEGF165 is commonly expressed in a wide
variety of human and animal tumours (Hanahan and Folkman,
1996) and has been shown to induce angiogenesis both in vitro
and in vivo (Leung et al, 1989; Plate et al, 1992). It is currently
believed that this diffusible molecule is probably a key mediator
of tumour angiogenesis (Ferrara, 1999). Indeed, the expression of
VEGF has been related to fundamental features of tumours, such
as growth rate (Kim et al, 1993), microvessel density (Toi et al,
1994) and vascular architecture (Drake, 1999) as well as the devel-
opment of tumour metastasis (Weidner et al, 1991). A correlation
between VEGF expression and survival has been noted in some
cancer patients (Maeda et al, 1996; Gasparini et al, 1997).
In light of its role in tumour angiogenesis, VEGF may be an
attractive target for anti-angiogenic therapeutic interventions
applied to the treatment of cancer. Renal cell carcinoma (RCC)
may be an excellent site to investigate VEGF targeted anti-angio-
genic therapies. RCC is the most common malignancy of the
kidney in adults and accounts for about 2% of all adult malignan-
cies (McLaughlin and Lipworth, 2000). Histopathologic evaluations
of RCC reveal it to be a highly vascularised neoplasm demonstrat-
ing clear evidence of abundant angiogenesis and abnormal blood
vessel development (Yoshino et al, 2000). Not surprisingly, several
studies have pointed to an important role for pro-angiogenic
growth factors in RCC. VEGF has been shown to be expressed in
renal cell carcinoma tissues and renal cell carcinoma cell lines (Sato
et al, 1994; Wang and Becker, 1997; Paradis et al, 2000). Serum
levels of VEGF often are elevated in RCC patients (Sato et al,
1999) and VEGF mRNA levels in renal cell carcinoma have been
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www.bjcancer.comreported to be higher than those found in surrounding normal
tissues (Takahashi et al, 1994; Berger et al, 1995). In addition,
elevated serum/urine VEGF levels have been shown to associated
with malignant progression and poor treatment outcome (Sato et
al, 1994; Baccala et al, 1998; Tomisawa et al, 1999; Ishizuka et
al, 2000; Jacobsen et al, 2000). Taken together, these ﬁndings
suggest that VEGF is one of the important factors involved in
the angiogenesis of RCC.
In the present study we evaluated the anti-angiogenic and anti-
tumour effects of VEGF antisense phosphorothioate oligodeoxynu-
cleotides (PS-ODNs) in a pre-clinical model of human RCC
(Caki-1).
MATERIALS AND METHODS
Cell culture
The clear cell RCC cell line Caki-1 was a gift from Dr Susan Knox
(Stanford University). Caki-1 cells were grown in Dulbecco’s modi-
ﬁed minimum essential medium (DMEM Invitrogen, Grand Island,
NY, USA) supplemented with 10% foetal bovine serum (FBS, Invi-
trogen, Grand Island, NY, USA), 1% penicillin-streptomycin
(Invitrogen, Grand Island, NY, USA) and 1% 200 mmol l
71 L-
glutamine (Invitrogen, Grand Island, NY, USA). The mouse heart
endothelial cell line (MHE) was a gift from Dr Robert Auerbach
(University of Wisconsin). MHE cells were grown in DMEM
supplemented with 10% heat inactivated foetal bovine serum, 1%
penicillin-streptomycin and 1% 200 mmol l
71 L-glutamine.
Human microvascular endothelial cell from the lung (HMVEC-L)
cells were obtained from Clonetics (San Diego, CA, USA).
HMVEC-L cells were grown in EBM-2-MV (Clonetics, San Diego,
CA, USA) supplemented with 5% FBS.
Caki-1 xenografts
Female nude mice (NCR, nu/nu), age 6–8 weeks were maintained
under speciﬁc-pathogen-free conditions (University of Florida
Health Science Centre) with food and water supplied ad libitum.
Animals were inoculated subcutaneously in a single ﬂank with
5610
6 tumour cells. When the tumours reached a size *200
mm
3, animals were randomly assigned to the different treatment
groups. All animal experiments have been carried out with ethical
committee approval. The ethical guidelines that were followed meet
the standards required by the Cancer Research UK guidelines
(Workman et al, 1998).
Phosphorothioate oligodeoxynucleotides (PS-ODNs)
Antisense and control PS-ODNs (20-mers) were custom synthe-
sised by Geno Mechanix (Alachua, FL, USA). PS-ODNs V515
was complementary to 5' UTR just up-stream of the translation
start site (AUG codon) of VEGF mRNA: 5'-CTC ACC CGT CCA
TGA GCC CG-3'. A scramble sequence: 5'-CAC CCT GCT CAC
CGC ATG GC-3'; sense sequence: 5'-CGG GCT CAT GGA CGG
GTG AG-3' and an inverted sequence: 5'-GCC CGA GTA CCT
GCC CAC TC-3', were used as PS-ODNs controls. All PS-ODNs
were suspended in sterile and endotoxin free water at a concentra-
tion of 1 mM, aliquoted and stored at 7208C.
DOTAP:DOPE liposome preparation
Cationic liposomes were prepared using the method described by
Tang and Hughes (1999). Brieﬂy, cationic lipid 1,2-dioleoyloxy-3-
(trimethylammonium) propane (DOTAP) was dissolved in chloro-
form and mixed with a helper lipid 1,2-dioleoyl-3-sn-
phosphatidylethanolamine (DOPE) (Avanti Polar-Lipids, Alabaster,
AL, USA) at a molar ratio of 1:1. The mixture was evaporated to
dryness in a round-bottomed ﬂask using a rotary evaporator at
room temperature. The resulting lipid ﬁlm was dried by nitrogen
for an additional 10 min to evaporate any residual chloroform.
The lipid ﬁlm was re-suspended in sterile water to a ﬁnal concen-
tration of 1 mg ml
71 based on the weight of cationic lipid. The
resultant mixtures were shaken in a water bath at 358C for
30 min. The suspensions were then sonicated using a Sonic
Dismembrator (Fisher Scientiﬁc, Pittsburgh, PA, USA) for 1 min
at room temperature to form homogenised liposomes. The parti-
cle-size distribution of liposomes was measured using a NICOMP
380 ZLS instrument (Santa Barbara, CA, USA). The average parti-
cle diameter was 144.0+77.0 nm. Liposomes were stored at 48C
and used within 3 months.
VEGF enzyme immunoassay
Caki-1 cells (1610
5) were set in 60 mm dishes and allowed to
attach overnight. The medium then was removed and replaced with
PS-ODNs in serum free medium with liposome (DOTAP:DOPE)
and incubated for 5 h. Fresh medium containing 10% FBS then
was added. After 24 h of incubation the VEGF concentration was
determined in the medium using a human VEGF immunoassay
kit (R & D Systems, Minneapolis, MN, USA).
VEGF relative quantitative RT–PCR
Caki-1 cells were set at 3610
5 in 100 mm dishes and allowed to
attach overnight. The cells were then treated with 1 mM VEGF anti-
sense or control PS-ODNs as described. Twenty-four hours later
the cells were collected and the total RNA was isolated using a
RNeasy Mini Kit (Qiagen, Valencia, CA, USA) and RNA concen-
trations were determined by UV spectrophotometry. A 2 mg total
RNA sample was used to reverse synthesize cDNA using Super-
script II reverse transcriptase (Invitrogen, Grand Island, NY,
USA). A 2.5 ml aliquot of the reverse transcriptase reaction product
then was used for the PCR reaction. VEGF PCR reactions were
carried out with a VEGF gene speciﬁc relative RT–PCR Kit
(Ambion, Austin, TX, USA). The PCR reactions were run 22 cycles
(denature 948C 30 s, anneal 608C 60 s, extension 728C6 0s )i na
DNA Engine 200 (MJ research, Waltham, MA, USA). PCR
products then were run in 2% agrose gel and stained by ethidium
bromide. The gels were visualised and analysed (Gel Doc 2000 gel
documentation system, Bio-Rad, Hercules, CA, USA).
Co-culture assay
Transwell (Corning, Corning, NY, USA) 6-well dishes with a
membrane pore size of 0.4 mM were used. Caki-1 cells were seeded
at 5610
4 in the transwell inserts and MHE or HMVEC-L cells
were plated at 5610
4 per well in the 6-well dishes and allowed
to attach overnight. The Caki-1 cell medium was then replaced
with serum free medium containing 1 mM V515 PS-ODNs or
control PS-ODNs liposome complexes (DOTAP:DOPE). After
5 h of treatment, medium containing 10% heat inactivated FBS
was added to yield a ﬁnal FBS concentration of 2.5%. The trans-
wells containing treated Caki-1 cells were assembled with 6-well
dished containing MHE and HMVEC-L cells and incubated at
378C for 48 h at which time the numbers of MHE or HMVEC-L
cells were determined by haemocytometer count.
Migration assay
Caki-1 cells were set at 1610
5 per well in 24-well dishes and
allowed to attach overnight. The Caki-1 cells then were treated
with 1 mM control or V515 PS-ODNs for 24 h. HTS FluoroBlok
inserts (Becton Dickinson, Franklin Lakes, NJ, USA) with a pore
size of 8.0 mm were assembled into the 24-well dish with the
Caki-1 cells. MHE or HMVEC-L cells were grown in T-150 ﬂasks
to about 80% conﬂuence. The endothelial cells were stained in
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71 Di-I (Molecular Probes, Eugene,
OR, USA) for 24 h, washed four times with PBS, collected, added
into the FluoroBlok inserts (5610
4 MHE or HMVEC-L) and incu-
bated for 24 h. The number of migrated endothelial cells then were
determined by direct measurement of the ﬂuorescence in the
bottom well using a CytoFluor 4000 plate reader (Perceptive
BioSystems, St. Paul, MN, USA).
Intradermal angiogenesis assay
Caki-1 cells (5610
4) were inoculated intradermally in a volume of
10 ml at four sites on the ventral surface of nude mice. One drop of
0.4% trypan blue was added to the cell suspension, which making
it lightly coloured, simplifying subsequent location of the sites of
injection. Three days later the mice were killed, the skin carefully
separated from the underlying muscle and the number of vessels
counted using a dissecting microscope (Sidky and Auerbach,
1976). Scoring of all of the reaction areas was carried out at the
same magniﬁcation (65) and only vessels readily detected at this
magniﬁcation were counted. The sites of injection, recognised by
local swelling and blue staining, were exposed by carefully remov-
ing fat or other tissue covering the area. All vessels that touched
the edge of the tumour inoculates were counted. All the animals
in the experiments were pre-coded and vessel counts in each
animal were scored twice. The resultant data points for each treat-
ment group were pooled for statistical analysis (Wilcoxon rank
sum test).
PS-ODNs up-take in tumour
FITC labelled control PS-ODNs were mixed with DOTAP:DOPE
in 200 ml 5% dextrose and injected into Caki-1 xenograft bearing
mice via the tail vein at a dose of 20 mg kg
71. Three hours later,
the mice were killed by CO2 asphyxiation, the tumours removed,
frozen in liquid nitrogen and 20 mm sections were cut. The sections
were photographed using a Zeiss Axioplan 2 Florescence Micro-
scope (Zeiss, Thornwood, NY, USA) within 3 days.
VEGF Western blot
VEGF antisense PS-ODNs V515 was injected tail vein at a dose of
10 mg kg
71. At various times after injection (24, 48 and 72 h), the
mice were killed, the tumours excised and frozen in liquid nitro-
gen. The tumours were then homogenised (Dounce tissue
grinder, Wheaton, Millville, NJ, USA) and the homogenates were
lysed on ice for 30 min with 1 ml of hypotonic buffer (20 mM
Tris-HCl, pH 6.8, 1 mM MgCl2,2m M EGTA, 0.5% Nonidet P-
40, 2 mM Phenylmethanesulphonyl ﬂuoride (PMSF), 200 u ml
71
Approtinin, 2 mgm l
71 leupetin) (Giannakakou et al, 1998) per
0.1 g tissue. Following a brief but vigorous vortex the samples were
centrifuged at 14000 r.p.m. for 10 min at 48C. A 30 ml aloquot of
each sample was mixed with 10 ml4 6 SDS–PAGE sample buffer
(0.3 M Tris-HCl, pH 6.8, 45% glycerol, 20% b-mercaptoethanol,
9.2% SDS and 0.04 g per 100 ml bromophenol blue) and heated
at 1008C for 10 min. Thirty ml of each sample was then analysed
by SDS–PAGE on a 12% separating gel and 3% stacking gel.
Following transfer, the membrane was immunoblotted using a
VEGF primary antibody (Sigma, Saint Louis, MS, USA) 1:1000
diluted in antibody solution (3% dry milk, 25 mM Tris, pH 7.5,
0.5 M NaCl, 0.05% Tween 20) overnight at 48C. After washing, a
secondary antibody labelled with horseradish peroxidase was
applied and incubated at room temperature for 1 h. Protein bands
were visualised and densitometry was performed.
Tumour growth delay assay
Once the Caki-1 xenografts reached a size of *200 mm
3, animals
were assigned randomly to various treatment groups. V515 or
control PS-ODNs were administrated via the tail vein with
DOTAP:DOPE liposomes at a dose of 5 mg kg
71 or 10 mg kg
71
on day 1 and day 4. Tumours were measured using callipers and
volumes were approximated by the formula, volume=1/6pab
2, with
a and b represent two perpendicular tumour diameters. The times
for the tumours in the various treatment groups to grow from
200 mm
3 to 1000 mm
3 were recorded and compared (Wilcoxon
rank sum test).
RESULTS
The ability to down-regulate VEGF expression by antisense PS-
ODNs treatment in Caki-1 tumour cells was ﬁrst evaluated in vitro.
The results showed that after 24 h treatment with 1 mM VEGF anti-
sense PS-ODNs (V515) delivered by cationic liposome
(DOTAP:DOPE), the medium VEGF level was signiﬁcantly
reduced to *35% that found in the control untreated group (from
a normal of 850 pg ml
7110
6 cells
71 to 300 pg ml
7110
6 cells
71)
(Figure 1). This effect was sequence, and target region speciﬁc.
Treating Caki-1 cells with liposome vehicles (DOTAP: DOPE) or
control scramble PS-ODNs did not affect VEGF levels. Similarly,
treatment with sense or inverted sequence PS-ODNs failed to
reduce VEGF expression. PS-ODNs treatment did not affect
Caki-1 cell viability and proliferation. This repression of VEGF
expression by V515 was dose dependent (Figure 2). For example,
a 24 h treatment with 0.5 mM, reduced the medium VEGF level
to 56% of control (P50.01) whereas a 1 mM dose down-regulated
the VEGF level to 22% of control (P50.05). VEGF mRNA levels in
different PS-ODNs treatment groups also were determined (Figure
3). The results indicated a marked inhibition of VEGF mRNA after
treatment with V515 which was absent in cells treated with scramble
PS-ODNs.
Since the goal of VEGF antisense therapy is to inhibit cancer cell
induced angiogenic signalling, experiments then were designed to
evaluate the impact of reducing tumour cell expression of VFGF
by antisense PS-ODNs treatment on endothelial cell growth and
migration. Because the ultimate goal was to examine the efﬁcacy
of VEGF antisense treatment in a human tumour model grown
in a mouse host, we evaluated the effect on both human
(HMVEC-L) and mouse (MHE) endothelial cells. Transwell co-
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Figure 1 VEGF levels in culture medium of Caki-1 tumour cells treated
with different antisense PS-ODNs. The cells were either untreated (Un-
treated) or treated with delivery vehicle only (DOTAP), a 1 mM dose of
control PS-ODNs sequences (Scramble, Sense and Inverted) or a 1 mM
dose of antisense PS-ODNs targeted to a speciﬁc sequence of VEGF
mRNA (V515). Each bar represents the mean+s.e. of three independent
experiments. The star indicates a signiﬁcant difference from the untreated
or control treated groups (P50.05, student’s t-test). The 100% VEGF
expression level of the untreated group corresponds to
*850 pg ml
7110
6 cells
71.
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tion between tumour cells and endothelial cells. Caki-1 tumour
cells were grown in transwells with 0.4 mm membrane pores. These
were chosen to allow the exchange of growth factors but without
direct cell–cell interactions. The effects of pretreating Caki-1
tumour cells with VEGF antisense PS-ODNs on endothelial cell
proliferation then were determined (Figure 4). The results showed
that compared to untreated Caki-1 cells, Caki-1 cells pre-treated
with V515 signiﬁcantly inhibited both HMVEC-L and MHE cell
proliferation. Once again, treating Caki-1 cells with a variety of
control PS-ODNs had no effect on HMVEC-L or MHE cell growth.
To test whether a reduction in VEGF expression by tumour cells
could affect endothelial cell migration, HMVEC-L or MHE cells
were stained with 10 mgm l
71 Di-I for 24 h and added into Fluor-
oblok inserts placed into 24 well dishes containing Caki-1 tumour
cells treated with either control or V515. The number of pre-
labelled endothelial cells which migrated through the 8 mm pore
size membranes in a 24 h period were quantiﬁed by determining
the ﬂuorescence intensity in the bottom well. The results showed
(Figure 5) that 24 h after co-culturing the two cell populations
*35% (P50.05) and 27% (P50.05) fewer MHE or HMVEC-L
cells respectively migrated through the membrane in the presence
of V515 treated Caki-1 cells compared to untreated or scramble
control PS-ODNs treated Caki-1 cells.
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Figure 2 VEGF levels in the culture medium of Caki-1 tumour cells trea-
ted with different doses (0.5, 1, 2, 5 mM) of VEGF antisense PS-ODNs
(V515). The 0 dose group was treated with scramble control PS-ODNs
(5 mM). Each square represents the mean+s.e. of three independent
experiments. The stars indicate signiﬁcant differences from 0 dose
(P50.05, student’s t-test).
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Figure 3 Message RNA levels in Caki-1 cells which were either un-
treated or treated with a 1 mM dose of scramble control sequence or VEGF
antisense PD-ODNs (V515). (A) Representative relative RT–PCR results,
each group was performed in duplicate; 18s indicates the RT–PCR ampli-
ﬁcation band of 18s ribosomal RNA. (B) Relative VEGF mRNA levels of
Caki-1 cells treated with different PS-ODNs. The values were obtained
by dividing the densitometer reading of the VEGF band by that of the
18s band. Each bar is the mean+s.e. of three experiments. The star
indicates a signiﬁcant difference (P50.05, student’s t-test).
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Figure 4 Effect of co-culturing Caki-1 tumour cells on the growth of en-
dothelial cells (MHE and HMVEC-L). Caki-1 cells were untreated or pre-
treated with DOTAP liposome vehicle, 1 mM scramble control PS-ODNs
or 1 mM V515 antisense PS-ODNs. Each bar represents the mean+s.e.
of three independent experiments. Stars indicate signiﬁcant difference
(P50.05, student’s t-test) from the untreated group.
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Figure 5 Impact of co-culturing Caki-1 tumour cells on ability of MHE
and HMVEC-L cells to migrate. Caki-1 cells were untreated or pre-treated
with DOTAP liposome vehicle, a 1 mM dose of scramble control or a 1 mM
dose of V515 antisense PS-ODNs. Each bar represents the mean+s.e. of
three experiments. The stars indicate a signiﬁcant difference (P50.05,
student’s t-test) from the untreated groups. The horizontal bars show
the levels of spontaneous migration of endothelial cells cultured alone;
the bar widths correspond to the mean values+1 s.e.
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British Journal of Cancer (2002) 87(1), 119–126 ã 2002 Cancer Research UKAlthough, the in vitro studies indicated that treating Caki-1
tumour cells with VEGF mRNA targeted antisense PS-ODNs
down-regulated VEGF protein production sufﬁciently to affect
the proliferation and migration of endothelial cells, it was impor-
tant to demonstrate that such treatments also could affect Caki-1
cell induction of angiogenesis in vivo. To examine this possibility
Caki-1 cells that had been treated with V515 or control PS-ODNs
were injected intradermally and the number of vessels induced
were counted 3 days later (Figure 6). While untreated Caki-1 cells
and control PS-ODNs treated Caki-1 cells had very similar angio-
genic potency in vivo (both groups induced *44–46 new vessels
in the assay period), the angiogenic potential of Caki-1 cells that
had been pre-treated with V515 antisense PS-ODNs (V515) was
found to be signiﬁcantly impaired; only *25 new blood vessels
were observed.
To evaluate the tumour up-take of PS-ODNs delivered by catio-
nic liposome (DOTAP:DOPE). FITC labelled PS-ODNs were
mixed with cationic liposome DOTAP:DOPE in 5% dextrose
and were injected via the tail vein at a dose of 20 mg kg
71 into
Caki-1 xenograft-bearing nude mice. Frozen sections prepared
3 h later showed the FITC labelled PS-ODNs to be efﬁciently deliv-
ered to the tumour (Figure 7). The heterogeneous PS-ODNs
uptake likely reﬂects the inhomogeneous distribution of blood
vessels in the tumour. To further conﬁrm the antisense effect of
V515 in vivo, tumour samples were collected at various times after
V515 injection. Western blot analysis of these samples showed
signiﬁcant reductions in VEGF levels at 24, 48 and 72 h, with
the maximum depression occurring at 48 h after treatment (Figure
8). These ﬁndings clearly indicate the delivery of VEGF antisense to
the tumour would result in a reduction in VEGF expression levels.
Subsequent experiments were undertaken to determine the anti-
tumour efﬁcacy of V515 antisense PS-ODNs when delivered
systemically by examining the effect of such treatments on Caki-
1 tumour growth. Caki-1 xenografts-bearing mice were treated
with two doses of VEGF antisense PS-ODNs V515 (5 or
10 mg kg
71) 1 and 4 days after the tumours reached a size of
*200 mm
3. The time for the tumours to grow from 200 mm
3
to 1000 mm
3 then was recorded (Figure 9). The data showed that
the median time for the tumours to grow to ﬁve times the starting
size was signiﬁcantly prolonged in the V515 antisense PS-ODNs
(V515) treated groups. Administrating two doses of 5 mg kg
71
caused a growth delay of *5.5 days (P50.05, Wilcoxon rank
sum test) while treatment with two 10 mg kg
71 doses led to a
tumour growth delay of *8 days. The latter treatment therefore
resulted in an approximately doubled the response of the tumours
compared to the tumours of untreated or scramble PS-ODNs
treated mice. No toxicity of such antisense PS-ODNs treatment
was observed. This included no signiﬁcant weight loss, no abnor-
mal movements or behaviour and no loose stools.
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Figure 6 Number of blood vessels induced 3 days after injecting 5610
4
Caki-1 cells intradermally in nude mice. Caki-1 cells were either untreated
or pre-treated with a 1 mM dose of PS-ODNs for 3 h. The Scramble group
refers to cells pre-treated with scramble control PS-ODNs, whereas the
V515 group represents Caki-1 cells pre-treated with VEGF antisense PS-
ODNs (V515). Each datum point represents one injection site, the bars
show the median of 16 sites in each group. The V515 treated group was
signiﬁcantly different from the untreated or scramble control groups
(P50.05, Wilcoxon rank sum test).
Figure 7 Uptake and distribution of FITC-labelled PS-ODNs in Caki-1
xenografts determined 3 h after an i.v. injection of a 20 mg kg
71 dose.
PS-ODNs were prepared with DOTAP:DOPE. Sections were 20 mm.
Caki-1 24 h 48 h 72 h
A
120
100
80
60
40
20
0
R
e
l
a
t
i
v
e
 
V
E
G
F
 
l
e
v
e
l
 
(
p
e
r
c
e
n
t
a
g
e
)
Control 24 h 48 h 72 h
Different time point after V515 treatment
B
Figure 8 VEGF protein levels in Caki-1 tumours at different time points
after treatment of 10 mg kg
71 VEGF antisense PD-ODNs (V515). (A) Re-
presentative VEGF Western blot results, showing two tumour samples of
each group; (B) Relative VEGF protein levels of Caki-1 tumours treated
VEGF antisense PD-ODNs (V515). Each bar is the mean+s.e. of six
tumours. The star indicates a signiﬁcant difference (P50.05, student’s t-
test).
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Anti-angiogenesis treatment strategies represent a new approach to
cancer management. Given that solid tumours cannot progress
effectively without the generation of new blood vessels, various
tacks have been taken to interfere with tumour angiogenesis. One
possible target which has received considerable attention is the
pro-angiogenic factor VEGF. VEGF can induce endothelial cell
proliferation and migration in vitro (Hanahan and Folkman,
1996; Soker et al, 1997) and angiogenesis in vivo (Leung et al,
1989; Plate et al, 1992). Its expression level has been associated
with a variety of tumours and correlated to treatment outcome
(Maeda et al, 1996; Gasparini et al, 1997). To date, attempts to
abrogate the angiogenic activity of VEGF have focused on inacti-
vating VEGF through the use of antibodies (Kim et al, 1993;
Mordenti et al, 1999) and soluble receptors (Lin et al, 1998), inhi-
biting VEGF receptor tyrosine kinases (Hennequin et al, 1999) or
suppressing VEGF message (Ellis et al, 1996; Smyth et al, 1997;
Nguyen et al, 1998). The latter relied on antisense oligonucleotides
or antisense RNA (Eguchi et al, 1991; Mercola and Cohen, 1995;
Phillips and Zhang, 2000) to modulate gene expression by disrupt-
ing RNA expression. While the inhibition of VEGF expression by
vector mediated gene transfer of antisense RNA has been shown
to lead to growth delays in several tumour models (Folkman and
Shing, 1992; Belletti et al, 1999; Kang et al, 2000; Nakashima et
al, 2000), the only reports of in vivo efﬁcacy when using VEGF
antisense oligonucleotides occurred in VEGF dependent tumour
models (Masood et al, 1997, 2001). In the present studies, we used
a VEGF independent tumour model of RCC (VEGF-R negative) to
evaluate the in vitro and in vivo efﬁcacy of a different VEGF anti-
sense PS-ODNs sequence (V515). Antisense oligodeoxynucleotide
technology provides an approach for inhibiting gene expression
with target speciﬁcity as a particular advantage (Stein and Cheng,
1993; Engelhard, 1998). Antisense oligonucleotides are easy to
produce in large quantities which make them potentially more
practical than antisense RNA vector delivery approaches.
In the present study, we investigated the anti-angiogenic and
anti-tumour effects of VEGF antisense PS-ODNs in a VEGF inde-
pendent tumour model of RCC. In vitro experiments showed that
the inhibition of VEGF production in Caki-1 tumour cells by anti-
sense PS-ODNs treatment signiﬁcantly reduced the ability of co-
cultured endothelial cells to proliferate (Figure 4) and migrate
(Figure 5). To minimise interference of other growth factors in
the serum, these studies were carried out under reduced serum
conditions. Importantly, suppressing tumour cell expression of
VEGF message impaired angiogenic responses in both human
and mouse endothelial cells. Subsequent in vivo studies demon-
strated that treating Caki-1 tumour cells with VEGF antisense
PS-ODNs signiﬁcantly impaired their ability to elicit an angiogenic
response when injected intradermally (Figure 6). These results not
only support the role of VEGF as an important pro-angiogenic
growth factor in Caki-1 cell induced angiogenesis, but also clearly
suggest that inhibition of cancer cell VEGF expression may ulti-
mately impact tumour growth. This belief was born out in
experiments evaluating the in vivo anti-tumour efﬁcacy of systemic
administration of VEGF antisense PS-ODNs which showed that
substantial tumour growth delays could be achieved with such
treatment (Figure 9).
The results of this study indicate a key role for the VEGF signal-
ling pathway in renal cell carcinoma angiogenesis. Treatment with
VEGF antisense PS-ODNs to down regulate VEGF production was
found to be effective at impairing the Caki-1 angiogenic signalling
both in vitro and in vivo. Most importantly the systemic adminis-
tration of VEGF antisense PS-ODNs to mice bearing macroscopic
tumours resulted in signiﬁcant inhibition of the growth of VEGF
independent RCC tumour model. Taken together, these ﬁndings
suggest that antisense PS-ODNs targeted to VEGF may have utility
in the management of renal cell carcinoma either alone or in
conjunction with conventional anti-cancer therapies.
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Figure 9 (A) Growth of median RCC Caki-1 tumours in nude mice
treated systemically with antisense PS-ODNs against VEGF. Mice were un-
treated, treated with 10 mg kg
71 scramble PS-ODNs, 5 mg kg
71 VEGF
antisense V515, or 10 mg kg
71 VEGF antisense V515 at the time indicated
by arrows. Each group consisted of 10 animals. (B) Tumour response of
Caki-1 xenografts treated systemically with antisense PS-ODNs targeted
to VEGF mRNA. Scramble control (Scramble) or VEGF antisense (V515)
PS-ODNs were administrated with cationic liposome (DOTAP:DOPE)
via the tail vein 1 and 4 days after the tumours reached a size of *200
mm
3. Liposome administration alone had no effect on Caki-1 tumour
growth (data not shown). Each circle represents a single tumour; the bars
show the response of the median tumour in each group of 10 mice. The
stars indicate signiﬁcant differences (P50.05, Wilcoxon rank sum test)
from the untreated and scramble control groups.
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